Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00101257
Other study ID # 1942.00
Secondary ID FHCRC-1942.00CDR
Status Completed
Phase Phase 1
First received January 7, 2005
Last updated May 5, 2010
Start date October 2004
Est. completion date March 2010

Study information

Verified date May 2010
Source Fred Hutchinson Cancer Research Center
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, stimulate the immune system in different ways and stop tumor cells from growing.

PURPOSE: This phase I trial is studying the side effects and best dose of cellular adoptive immunotherapy in treating patients with stage III or stage IV ovarian cancer or primary peritoneal cancer.


Description:

OBJECTIVES:

Primary

- Determine the safety and toxicity of autologous CD4-positive antigen-specific T cells in patients with stage III or IV ovarian epithelial cancer or primary peritoneal cavity cancer.

- Determine the duration of in vivo persistence of this drug in these patients.

Secondary

- Determine the antitumor effect of this drug in these patients.

OUTLINE: This is a dose-escalation study.

Patients undergo leukapheresis for collection of T cells. Responder T cells are stimulated in vitro with autologous peripheral blood mononuclear cell-derived dendritic cells pulsed with NY-ESO-1 immunogenic peptides. Patients receive autologous CD4-positive antigen-specific T cells IV over 30 minutes.

Cohorts of 3-6 patients receive escalating doses of autologous CD4-positive antigen-specific T cells until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed at 4, 8, and 12 weeks and then periodically thereafter for survival.

PROJECTED ACCRUAL: A total of 9-18 patients will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date March 2010
Est. primary completion date
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed stage III or IV ovarian epithelial cancer or primary peritoneal cavity cancer meeting 1 of the following criteria:

- Progressive* or persistent* disease during or after primary chemotherapy

- Recurrent disease < 6 months after completion of primary therapy that had resulted in a complete response

- Persistent* or recurrent disease after second-line or additional therapies NOTE: *Progression or persistence can be based on serological (CA 125 > 100 U/mL OR 2 times baseline), radiographic (measurable or evaluable disease), or second-look surgical findings

- Tumor expressing NY-ESO-1 determined by IHC or RT-PCR

- HLA type expressing DPB*0401, DPB1*0201, DRB1*07

- No CNS metastases

PATIENT CHARACTERISTICS:

Age

- 18 to 75

Performance status

- Karnofsky 70-100%

Life expectancy

- More than 16 weeks

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Creatinine = 2.0 mg/dL

Cardiovascular

- No congestive heart failure*

- No clinically significant hypotension*

- No symptoms of coronary artery disease*

- No cardiac arrhythmias on EKG requiring drug therapy*

- No history of cardiovascular disease*

- No other significant cardiovascular abnormalities* NOTE: *Patients with any of the above undergo a stress test and/or echocardiography before being determined ineligible for study participation

Pulmonary

- FEV_1 = 60% of predicted*

- DLCO = 55%* NOTE: *Patients with clinically significant pulmonary dysfunction only

Other

- Not pregnant or nursing

- Fertile patients must use effective contraception

- HIV negative

- No active infection

- No oral temperature > 38.2°C within the past 72 hours

- No systemic infection requiring chronic maintenance or suppressive therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

- No other concurrent immunotherapy (e.g., interleukins, interferons, vaccines, intravenous immunoglobulin, or expanded polyclonal tumor-infiltrating lymphocytes or lymphokine-activated killer cell therapy)

Chemotherapy

- See Disease Characteristics

- At least 3 weeks since prior standard or experimental chemotherapy

Endocrine therapy

- No concurrent systemic corticosteroids except for treatment-related toxicity

Radiotherapy

- At least 3 weeks since prior radiotherapy

Surgery

- See Disease Characteristics

Other

- At least 3 weeks since prior immunosuppressive therapy

- More than 3 weeks since prior investigational drugs and recovered

- No other concurrent investigational agents

- No concurrent pentoxifylline

Study Design

Primary Purpose: Treatment


Intervention

Biological:
therapeutic autologous lymphocytes


Locations

Country Name City State
United States Fred Hutchinson Cancer Research Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Fred Hutchinson Cancer Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and toxicity Yes
Primary Duration of in vivo persistence No
Primary Antitumor effects No
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2